Cita APA (7a ed.)
King, W. (2022). Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer. Oncology Nurse-APN/PA, 15(3), 21.
Cita Chicago Style (17a ed.)
King, William. "Darolutamide Plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer." Oncology Nurse-APN/PA 15, no. 3 (2022): 21.
Cita MLA (9a ed.)
King, William. "Darolutamide Plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer." Oncology Nurse-APN/PA, vol. 15, no. 3, 2022, p. 21.
Precaución: Estas citas no son 100% exactas.